G B Appel

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. doi request reprint Membranoprolferative glomerulonephritis - mechanisms and treatment
    Gerald B Appel
    Columbia University Medical Center, New York, NY 10032, USA
    Contrib Nephrol 181:163-74. 2013
  2. doi request reprint Detecting and controlling diabetic nephropathy: what do we know?
    Gerald Appel
    Clinical Nephrology, Columbia University, New York, NY 10032, USA
    Cleve Clin J Med 80:209-17. 2013
  3. doi request reprint New diagnostic tests and new therapies for glomerular diseases
    Gerald B Appel
    Glomerular Kidney Disease Center, Division of Nephrology, Columbia University Medical Center, and College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Blood Purif 35:81-5. 2013
  4. doi request reprint New and future therapies for lupus nephritis
    Gerald B Appel
    Presbyterian Hospital, New York, NY 10032, USA
    Cleve Clin J Med 79:134-40. 2012
  5. ncbi request reprint Use of mycophenolate mofetil in autoimmune and renal diseases
    Gerald B Appel
    Department of Nephrology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Transplantation 80:S265-71. 2005
  6. ncbi request reprint Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection
    Gerald B Appel
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Prog Cardiovasc Dis 47:105-15. 2004
  7. doi request reprint The treatment of acute interstitial nephritis: More data at last
    G B Appel
    Columbia University College of Physicians and Surgeons, New York, New York, USA
    Kidney Int 73:905-7. 2008
  8. ncbi request reprint Course and prognosis of human immunodeficiency virus-associated nephropathy
    L Carbone
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York
    Am J Med 87:389-95. 1989
  9. ncbi request reprint Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature
    J Lin
    Division of Nephrology, Department of Medicine, Columbia University, New York Presbyterian Hospital, New York, N Y, USA
    Am J Nephrol 21:351-6. 2001
  10. ncbi request reprint Heavy chain deposition disease: the disease spectrum
    N Kambham
    Department of Pathology, Renal Pathology Laboratory, New York, NY, USA
    Am J Kidney Dis 33:954-62. 1999

Detail Information

Publications54

  1. doi request reprint Membranoprolferative glomerulonephritis - mechanisms and treatment
    Gerald B Appel
    Columbia University Medical Center, New York, NY 10032, USA
    Contrib Nephrol 181:163-74. 2013
    ..These patients need to be evaluated in a different fashion and receive different therapy than those patients with MPGN forms associated with immunoglobulin deposition...
  2. doi request reprint Detecting and controlling diabetic nephropathy: what do we know?
    Gerald Appel
    Clinical Nephrology, Columbia University, New York, NY 10032, USA
    Cleve Clin J Med 80:209-17. 2013
    ..The major ways to prevent or slow its progression are by reducing blood pressure, controlling blood sugar, and inhibiting the renin-angiotensin-aldosterone axis. New therapeutic agents are also being tried...
  3. doi request reprint New diagnostic tests and new therapies for glomerular diseases
    Gerald B Appel
    Glomerular Kidney Disease Center, Division of Nephrology, Columbia University Medical Center, and College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Blood Purif 35:81-5. 2013
    ....
  4. doi request reprint New and future therapies for lupus nephritis
    Gerald B Appel
    Presbyterian Hospital, New York, NY 10032, USA
    Cleve Clin J Med 79:134-40. 2012
    ..The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all...
  5. ncbi request reprint Use of mycophenolate mofetil in autoimmune and renal diseases
    Gerald B Appel
    Department of Nephrology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Transplantation 80:S265-71. 2005
    ..This article will review the published data and the experience of two major New York medical centers with the use of MMF in autoimmune and renal diseases...
  6. ncbi request reprint Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection
    Gerald B Appel
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Prog Cardiovasc Dis 47:105-15. 2004
  7. doi request reprint The treatment of acute interstitial nephritis: More data at last
    G B Appel
    Columbia University College of Physicians and Surgeons, New York, New York, USA
    Kidney Int 73:905-7. 2008
    ..The study by González et al., although it has limitations, provides solid support for the early use of corticosteroids in the treatment of drug-related AIN...
  8. ncbi request reprint Course and prognosis of human immunodeficiency virus-associated nephropathy
    L Carbone
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York
    Am J Med 87:389-95. 1989
    ..Patient survival is dependent upon the stage of HIV infection. These findings may prove useful in devising more effective strategies for the care of this growing patient population...
  9. ncbi request reprint Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature
    J Lin
    Division of Nephrology, Department of Medicine, Columbia University, New York Presbyterian Hospital, New York, N Y, USA
    Am J Nephrol 21:351-6. 2001
    ..The close temporal association as well as evidence from murine models of GVHD support a pathogenetic association between GVHD and the development of MG...
  10. ncbi request reprint Heavy chain deposition disease: the disease spectrum
    N Kambham
    Department of Pathology, Renal Pathology Laboratory, New York, NY, USA
    Am J Kidney Dis 33:954-62. 1999
    ..There is no effective treatment for this condition, and virtually all patients progress to chronic renal failure...
  11. ncbi request reprint Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features
    Jordan L Rosenstock
    Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Kidney Int 63:1450-61. 2003
    ..Controversy surrounds the relatedness of fibrillary glomerulonephritis (FGN) and immunotactoid glomerulonephritis (IT)...
  12. ncbi request reprint Antiphospholipid antibody syndrome and renal disease
    R E Joseph
    Department of Medicine, Division of Nephrology, Columbia Presbyterian Medical Center, New York, New York, USA
    Curr Opin Nephrol Hypertens 10:175-81. 2001
    ..The use of immunosuppressive agents has had no dramatic effect on antiphospholipid antibody titers and little clinical effect on thrombotic events...
  13. ncbi request reprint Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection
    J T Cheng
    Department of Medicine at Harlem Hospital Center, New York, New York 10037, USA
    J Am Soc Nephrol 10:1566-74. 1999
    ..Although hypocomplementemia, cryoglobulinemia, and more prominent hypertension and microscopic hematuria may provide clues to the presence of HCV-GD, renal biopsy is essential to differentiate HCV-GD from HIV-associated nephropathy...
  14. doi request reprint An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases
    Alice S Appel
    Columbia University Medical Center, New York, NY 10032, USA
    Nat Clin Pract Nephrol 5:132-42. 2009
    ..Only through large, collaborative, controlled trials will the true role of MMF be defined for each glomerular disease...
  15. pmc Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation
    Ben Sprangers
    Department of Medicine, Division of Nephrology, Columbia University, College of Physicians and Surgeons, New York, New York, USA
    Clin J Am Soc Nephrol 5:790-7. 2010
    ..It is known that iMN may recur after kidney transplantation, causing proteinuria, allograft dysfunction, and allograft loss. Limited data regarding the frequency and treatment of recurrent iMN are available...
  16. ncbi request reprint Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis
    Samih H Nasr
    Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    Kidney Int 65:85-96. 2004
    ..We report a novel phenotype of glomerular injury that does not conform to any of the previously described patterns of glomerular involvement by monoclonal gammopathy...
  17. ncbi request reprint Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes
    S H Nasr
    Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Kidney Int 69:616-20. 2006
  18. ncbi request reprint Renal monoclonal immunoglobulin deposition disease: the disease spectrum
    J Lin
    Division of Nephrology, Department of Medicine, Columbia University, New York-Presbyterian Hospital, 630 W. 168th Street, New York, NY 10032, USA
    J Am Soc Nephrol 12:1482-92. 2001
    ..0 mg/dl, emphasizing the importance of early detection. On multivariate analysis, initial creatinine was the only predictor of renal and patient survival in pure MIDD, underscoring the prognostic significance of the renal involvement...
  19. ncbi request reprint Mycophenolate mofetil for the treatment of interstitial nephritis
    Dean C Preddie
    Department of Medicine Division of Nephrology, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH4 124, New York, NY 10032, USA
    Clin J Am Soc Nephrol 1:718-22. 2006
    ..4 mo. MMF was well tolerated by all patients. It is concluded that MMF is a useful therapeutic option for steroid-resistant AIN and may be considered as potential first-line therapy in select populations...
  20. doi request reprint Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
    Jai Radhakrishnan
    Department of Medicine, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA
    Kidney Int 77:152-60. 2010
    ..Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC...
  21. pmc Proliferative glomerulonephritis with monoclonal IgG deposits
    Samih H Nasr
    Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Am Soc Nephrol 20:2055-64. 2009
    ..We conclude that proliferative glomerulonephritis with monoclonal IgG deposits does not seem to be a precursor of myeloma in the vast majority of patients...
  22. pmc Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients
    Samih H Nasr
    Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Clin J Am Soc Nephrol 4:22-32. 2009
    ..Dense deposit disease (DDD) is a rare disorder that most commonly affects children. This study reports the largest North American series addressing clinicopathologic and outcome differences in children and adults...
  23. pmc Renal transplantation in familial dysautonomia: report of two cases and review of the literature
    Yelena Rekhtman
    Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin J Am Soc Nephrol 5:1676-80. 2010
    ..Transplant was performed after 3 months on intermittent hemodialysis (HD) in the first case and after 1 month on twice-weekly continuous veno-venous hemodialysis (CVVHD) in the second case...
  24. pmc Pauci-immune crescentic glomerulonephritis superimposed on diabetic glomerulosclerosis
    Samih H Nasr
    Department of Pathology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, VC14 224, New York, NY 10032, USA
    Clin J Am Soc Nephrol 3:1282-8. 2008
    ..Pauci-immune necrotizing and crescentic glomerulonephritis (PNCGN) superimposed on diabetic glomerulosclerosis (DGS) is a rare occurrence. Only limited data on this dual glomerulopathy are available...
  25. doi request reprint A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy
    Andrew S Bomback
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Nephrol Dial Transplant 25:3442-6. 2010
    ..Whereas prior European-American patients with lipoprotein glomerulopathy were found to have the previously reported apoE Kyoto genotype, the patient presented here was found to have a novel mutation that we have named apoE Las Vegas...
  26. ncbi request reprint Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate
    G S Markowitz
    Department of Pathology, Columbia College of Physicians and Surgeons, New York, New York 10032, USA
    J Am Soc Nephrol 12:1164-72. 2001
    ..These data provide the first association of collapsing FSGS with toxicity to a therapeutic agent...
  27. ncbi request reprint COX-2 inhibitors and the kidney
    G B Appel
    Columbia Presbyterian Medical Center, New York, USA
    Clin Exp Rheumatol 19:S37-40. 2001
    ..Judicious use of COX-2 inhibitors in high-risk patients (such as those with chronic renal insufficiency, diabetes or congestive heart failure) will lead to a decreased incidence of adverse renal events...
  28. pmc Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
    Gerald B Appel
    Department of Nephrology, Columbia University, New York, New York, USA
    J Am Soc Nephrol 20:1103-12. 2009
    ..Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis...
  29. ncbi request reprint Improved outcomes in nephrotic syndrome
    Gerald B Appel
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    Cleve Clin J Med 73:161-7. 2006
    ..Depending on the condition, additional treatment may include corticosteroids, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), cyclosporine, cytotoxic agents, or mycophenolate...
  30. ncbi request reprint Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib
    G S Markowitz
    Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Nephrol 59:137-42. 2003
    ..These cases enlarge the spectrum of potential renal toxicities of the COX-2-specific non-steroidal anti-inflammatory drugs...
  31. ncbi request reprint Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients
    A Matalon
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, 10032, USA
    Clin Nephrol 56:271-8. 2001
    ..Predictors of response to PP include early initiation of treatment after recurrence and possibly an early recurrence of disease...
  32. pmc Recurrent glomerulonephritis after renal transplantation: an unsolved problem
    William A Golgert
    Division of Nephrology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Clin J Am Soc Nephrol 3:800-7. 2008
    ..This study analyzed prevalence and outcome of recurrent glomerulonephritis from various registries...
  33. ncbi request reprint Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases
    Premila Bhat
    Department of Medicine Nephrology, Columbia University Medical Center, New York, NY, USA
    Am J Kidney Dis 50:641-4. 2007
    ..Additional clinical studies should be planned...
  34. doi request reprint Glomerular disease: why is there a dearth of high quality clinical trials?
    David E Leaf
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Kidney Int 78:337-42. 2010
    ....
  35. ncbi request reprint Analysis of metabolic parameters as predictors of risk in the RENAAL study
    Gerald B Appel
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Diabetes Care 26:1402-7. 2003
    ....
  36. ncbi request reprint Hyperlipidemia and thrombotic complications in patients with membranous nephropathy
    Thomas L Nickolas
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Semin Nephrol 23:406-11. 2003
    ..Prospective trials in the future will provide definitive information on how to best treat these abnormalities...
  37. pmc Familial collapsing focal segmental glomerulosclerosis
    V Liakopoulos
    Departments of Medicine and Division of Nephrology of Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Nephrol 75:362-8. 2011
    ..The course and response to treatment differed dramatically among members of the same family...
  38. ncbi request reprint The IgA nephropathy treatment dilemma
    G B Appel
    Department of Medicine, Division of Nephrology, Columbia Presbyterian, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Kidney Int 69:1939-44. 2006
    ....
  39. ncbi request reprint Racial and socioeconomic factors in glomerular disease
    D Halevy
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Semin Nephrol 21:403-10. 2001
    ..Whether racial and socioeconomic data should be used in treating individual patients, and how, remains an area of controversy...
  40. ncbi request reprint Minimal change disease in systemic lupus erythematosus
    G K Dube
    Department of Pathology, Columbia University, New York Presbyterian Hospital, NY, USA
    Clin Nephrol 57:120-6. 2002
    ..Proper recognition of this entity requires careful integration of the renal biopsy immunofluorescence and electron microscopic findings...
  41. ncbi request reprint Collapsing glomerulopathy
    Joshua A Schwimmer
    Division of Nephrology, Department of Medicine, Columbia College of Physicians and Surgeons, New York, NY, USA
    Semin Nephrol 23:209-18. 2003
    ..The role of other immunosuppressive agents such as mycophenolate mofetil in the treatment of collapsing FSGS remains to be defined. Prospective clinical trials are needed to define optimal therapy of this aggressive form of FSGS...
  42. ncbi request reprint Membranoproliferative glomerulonephritis type II (dense deposit disease): an update
    Gerald B Appel
    Columbia University, Department of Nephrology, New York, New York, USA
    J Am Soc Nephrol 16:1392-403. 2005
    ..The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II...
  43. doi request reprint Updates on the treatment of lupus nephritis
    Andrew S Bomback
    Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Am Soc Nephrol 21:2028-35. 2010
    ..Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials...
  44. ncbi request reprint Fludarabine treatment of cryoglobulinemic glomerulonephritis
    Jordan L Rosenstock
    Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    Am J Kidney Dis 40:644-8. 2002
    ..Transient blindness and neutropenia were seen in another patient. These results suggest that fludarabine may be a useful treatment in cryoglobulinemia with glomerulonephritis, although its use may be accompanied by side effects...
  45. pmc NPHS2 variation in focal and segmental glomerulosclerosis
    Stephen J Tonna
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    BMC Nephrol 9:13. 2008
    ..Homozygous or compound heterozygous mutations in the podocin gene NPHS2 are found in 10-30% of pediatric cases of steroid resistant nephrosis and/or FSGS...
  46. ncbi request reprint Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
    W Kline Bolton
    Department of Medicine, University of Virginia Health System, Charlottesville, Va 2908 0133, USA
    Am J Nephrol 24:32-40. 2004
    ..This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus...
  47. ncbi request reprint Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
    R Graham Barr
    Columbia Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA
    Nephrol Dial Transplant 18:2039-46. 2003
    ..However, no study has simultaneously examined socio-economic status. We studied rates of progression of PLN among a tri-ethnic population with respect to socio-economic status and race/ethnicity...
  48. ncbi request reprint Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  49. pmc NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
    Hiroyasu Tsukaguchi
    Department of Laboratory Medicine, University of Tokushima, Tokushima, Japan
    J Clin Invest 110:1659-66. 2002
    ..Identification of R229Q mutations may be of clinical importance, as NPHS2-associated disease appears to define a subgroup of FSGS patients unresponsive to corticosteroids...
  50. ncbi request reprint The classification of glomerulonephritis in systemic lupus erythematosus revisited
    Jan J Weening
    Academic Medical Center, University of Amsterdam, The Netherlands
    Kidney Int 65:521-30. 2004
    ..We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification...
  51. ncbi request reprint The classification of glomerulonephritis in systemic lupus erythematosus revisited
    Jan J Weening
    Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    J Am Soc Nephrol 15:241-50. 2004
    ..We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification...
  52. ncbi request reprint To treat or not to treat IgA nephropathy? That is the question!
    Gerald B Appel
    Clin J Am Soc Nephrol 1:347-8. 2006
  53. ncbi request reprint Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Andrew M Tershakovec
    Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
    Diabetes Care 31:445-7. 2008
    ..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
  54. doi request reprint Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial
    Mario H Cardiel
    Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
    Arthritis Rheum 58:2470-80. 2008
    ....